Chargement en cours...

Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis

Anti-programmed cell death-1 (PD-1) antibodies has been approved to treat HCC. Some PD-1 ligands (PD–L1 and PD–L2) negative tumors respond to treatment of anti-PD-1 antibodies, and this fact may be caused by the expression of PD-1 ligands on non-tumor cells. PD–L1 was recently found to be expressed...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Sci Rep
Auteurs principaux: Yasuoka, Hidetaka, Asai, Akira, Ohama, Hideko, Tsuchimoto, Yusuke, Fukunishi, Shinya, Higuchi, Kazuhide
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group UK 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7316832/
https://ncbi.nlm.nih.gov/pubmed/32587357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-67497-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!